in the extracellular portion of the membrane bound mucin MUC1, is shed into the bloodstream. An increase in the serum CA 15-3 shed ectodomain is associated with progression of carcinoma in patients.
The high level of CA 15-3 associated with larger burden of occult disease. There are many studies showing worse prognosis in patients with high concentration of CA 15-3. 7, 8 The CA 15-3 is independent predictor of recurrence and advanced breast cancer. 9 During follow-up of patients, this CA15-3 marker used in surveillance of patient with diagnosed breast cancer and monitoring of treatment. 10 It remains raised in 100% case of patient with progressive disease, decrease of value in 81% of patient to response to full treatment modality.
Aim and objectives
• Clinico-pathological study of the patients with breast cancer • Evaluation of CA15-3 as a prognostic marker in terms of response to treatment • Evaluation of CA15-3 in patients with residual tumour, recurrence and distant metastasis Table 2 .
METHODS

Patients
Serum CA 15-3 concentration was determined by Enzyme Immunoassay Kit based on the principle of a solid phase enzyme-linked immunosorbent assay (ELISA), purchased from Calbiotech, Inc, USA, CA 94404.
The lower limit of sensitivity was 1.2 U/ml and the established cut-off was 24.95U/ml determined by 95 percentile of 25 benign breast disease and mastitis patients and upper normal limit of CA 15-3 was calculated (24.95U/ml). Table 1 .
CA 15-3 serum levels were evaluated pre-treatment, Posttreatment (at 7 days after full treatment modality) and at 6 months follow-up in each patients. Mean serum value of CA 15-3 prior to treatment was significantly higher 50.6 U/ml as compared to mean value of CA 15-3 after 7 days of Full treatment modality 24.07 U/ml. 74/85 of patients (%) had higher serum levels of CA 15-3 before treatment (consisting in surgery, radio-or chemo-therapy) whereas only 21/85 of cases (%) displayed values over cut-off after full treatment. Author found that decreased serum levels of CA 15-3 in these patients were statistically significant (Test t-test. p <0.0001).
In addition, author also found a significant direct correlation between CA 15-3 serum levels before treatment and follow-up at 6 months (p <0.0001). Statistically significant difference in prognosis (outcome) was found in correlation chi square analysis by following factors: 1) tumour size 2) histological types.
No statistically significant difference in prognosis (outcome) was found in correlation chi square analysis by following factors: 1) lymph node 2) grade 3) hormonal receptor.
DISCUSSION
The problem of breast cancer has always existed and increasing in most countries. Breast cancer mortality can only be reduced by detecting the tumour at the earlier stage. Serum marker in breast cancer are helpful for clinicians in providing more effective management of the disease. Main use of CA 15-3 is to monitor the breast cancer patient response to treatment and for early breast cancer recurrence or metastasis. In this study 85 cases of breast cancer, change in the value of serum CA15-3 after full modality of treatment and follow-up were assessed and its relate to outcome of patient (prognostic significance). CA15-3 levels were also compared with tumour size, histological type, grade and Luminal type and its role in prognostic significance. 25 patients with benign breast disease and mastitis included in control group. Upper normal value was calculated 24.95U/ml by 95 percentiles.
The main use of CA 15-3 is to monitor the breast cancer patient response to treatment and for early breast cancer recurrence, residual tumour or distant metastasis. CA 15-3 can be used as a marker only if cancer is producing elevate amounts of it. However, it may be useful as a prognostic marker even in a small percentage of patients with localized breast cancer showing increased levels of CA 15-3. If CA 15-3 is initially elevated may be used to monitor treatment and when repeated on a regular basis, to detect early recurrence and residual tumour; CA 15-3 is not useful when breast cancer is detected early by other examinations. In general, higher levels of CA 15-3 are correlated with a larger tumour burden and a more advanced disease. The serum levels of CA 15-3 increase as cancer develops.
An initial elevation of CA 15-3 that does not return to the normal range, is an indicator of lack of response to treatment and represents an adverse prognostic factor. Present study shows a significant correlation between CA 15-3 and the response to treatment. In fact, author demonstrated a continuous increase of the marker in patients with metastatic disease that had subsequently developed relapse, recurrence, distant metastasis and even death by analyzing CA 15-3 serum concentrations in breast cancer patients during follow-up. Similar observations were reported by different authors.
For example, FG Ebeling et al showed that following successful treatment serum CA 15-3 value fell significantly below pre-treatment level(p=0.000). 2 Sujiezhang et al, showed elevated serum marker CA15-3, CEA, VGEF, CA125 in recurrence group during followup of patients.
In line with the findings, Hiba Qassem Ali and coworkers showed that high preoperative levels of CA 15-3 can predict adverse outcome in patients with larger tumour size of breast cancer. In particular, present study showed that patients presenting CA15-3 levels over 24.95U/ml (cut-off) have poor prognostic significance with concentrations <24.95U/ml in larger tumour size of breast cancer patients. The aim of this prospective study was to determine the applicability of serum CA 15-3 assay in the detection of prognostic significance in term of outcome (residual tumour, recurrence, distant metastasis and death) after full treatment modality and during the follow up.
present results demonstrated that CA 15-3 levels are frequently higher before treatment than after treatment of primary tumour. In addition, author found that higher levels of CA 15-3 in patients prior to treatment are more frequently associated with disease progression and worse prognostic significance (outcome) compared to patients with lower levels of CA 15-3. The most likely explanation can be that patients with elevated levels of CA 15-3 may harbor micro metastatic disease undetectable with the standard diagnostic procedures. Using chi-square test and t-test analysis, author show that the only independent variables are increased levels of CA 15-3 and poor prognostic significance. Finally, pesent study demonstrated the important role of this marker in monitoring the efficacy of post-treatment therapies (i.e. Surgery, chemo or radiotherapy).
CONCLUSION
In conclusion, the present study suggests serum CA 15-3 as an independent prognostic factor as well as having additive effect with other poor prognostic factors.
